Levitra

Vardenafil, the active ingredient in Levitra, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a buccal formulation for buccal use. It treats erectile dysfunction in adult males.

GNH USA supplies Levitra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levitra is a PDE5 inhibitor indicated for conditions affecting male sexual function.

Erectile dysfunction: improves the ability to achieve and maintain an erection sufficient for sexual activity when sexual stimulation occurs.

Common Side Effects: - Headache: mild to moderate pain often reported. - Flushing: warmth and redness of the face or upper body. - Nasal congestion: sensation of a blocked nose. - Dyspepsia: upset stomach or indigestion. - Back pain: transient muscular discomfort. - Visual changes: blurred vision or color tinge.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours. - Sudden vision loss: abrupt loss of vision in one or both eyes. - Sudden hearing loss: rapid decrease or loss of hearing. - Severe hypotension: marked drop in blood pressure causing dizziness. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Levitra, clinicians should consider several safety factors.

Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina. Nitrate therapy: avoid concurrent use with nitrates due to risk of severe hypotension. Blood pressure monitoring: do not use in uncontrolled hypertension or hypotension. Renal/hepatic impairment: assess organ function and adjust dose if needed. Drug interactions: review all concomitant medications for potential interactions. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Levitra may interact with several medicines that affect its metabolism or hemodynamic effects.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): can cause dangerous blood‑pressure drops. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vardenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., doxazosin): may cause additive hypotension. - Antihypertensives (e.g., beta‑blockers): monitor blood pressure. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Protease inhibitors (e.g., ritonavir): may increase plasma levels.